Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

Mosaic gained ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, in the deal, which it hopes to advance in biomarker-defined indications.

NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...

The biotech and hospital have expanded their collaboration, with Alcyone now advancing a gene therapy for Batten disease that the hospital was developing.

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

The subcutaneous Perjeta-Herceptin formulation, Phesgo, was a top driver of sales growth in the first quarter of 2025.

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The draft guidance make the regimen available to HR-positive early-stage breast cancer patients with lymph node-positive disease through the Cancer Drugs Fund.

Etiome will use its Temporal Biodynamics platform to stage serious, progressive chronic diseases and develop targeted therapeutics.